Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Director | June 08, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2036-06-08 | Direct | 8,590 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 8,590 · Balance 8,590 F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 11, 2026 00:00 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 8,590 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266278 · ownership.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,590 Underlying: Common Stock · 8,590 shares Expires 2036-06-08 F1 · derivative.exercise_date: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 24, 2026 Filed May 8, 2026 20:44 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-214815 · ownership.xml · derivative · entry 3 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter. F3 · derivative.expiration_date: The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter. Read SEC document |
| January 24, 2026 Filed May 8, 2026 20:44 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-214815 · ownership.xml · nonDerivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 19, 2025 Filed May 8, 2026 20:44 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 395,680 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001193125-26-214815 · ownership.xml · derivative · entry 2 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,680 Underlying: Common Stock · 395,680 shares Expires 2035-09-19 F2 · derivative.exercise_date: The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 22:34 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006781 · tm254730-1_4seq1.xml · derivative · entry 2 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_price: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · price: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 22:34 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006781 · tm254730-1_4seq1.xml · nonDerivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 20:02 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109525 · tm2426349-5_4seq1.xml · nonDerivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,942 F1 · kind: This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:33 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007294 · tm244260-4_4seq1.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:12 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 2,859 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008604 · tm234943-4_4seq1.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:29 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072191 · tm2218714-8_4seq1.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:16 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 37,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005694 · form4-12032021_021230.xml · derivative · entry 2 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:16 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 37,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005694 · form4-12032021_021230.xml · nonDerivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:11 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 3,334 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002616 · form4-05202021_040547.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 01:04 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001415889-21-001851 · form4-04022021_060410.xml · derivative · entry 2 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-04-01 F3 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one-half of the shares underlying the option shall vest on April 1, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 01:04 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 37,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001851 · form4-04022021_060410.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,695 Underlying: Common Stock · 37,695 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. The restricted stock units will vest in full on December 1, 2021, subject to the Reporting Person's continued service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of service or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person. F2 · derivative.expiration_date: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. The restricted stock units will vest in full on December 1, 2021, subject to the Reporting Person's continued service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of service or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.